{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:21:57Z","timestamp":1772886117370,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"DOI":"10.7759\/cureus.76988","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:37:52Z","timestamp":1736156272000},"source":"Crossref","is-referenced-by-count":1,"title":["Midodrine and Weekly Albumin Therapy in Patients With Cirrhosis and Diuretic Intractable or Recurrent Ascites: A Case-Control Study"],"prefix":"10.7759","author":[{"given":"Gourav J","family":"Borah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayan","family":"Malakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajanikant  R","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321790","article-title":"Guidelines on the management of ascites in cirrhosis","volume":"70","author":"Aithal GP","year":"2021","unstructured":"Aithal GP, Palaniyappan N, China L, et al.. Guidelines on the management of ascites in cirrhosis. Gut. 2021, 70:9-29. 10.1136\/gutjnl-2020-321790","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225226","article-title":"Management of ascites in patients with cirrhosis: an update","volume":"10","author":"Zaccherini G","year":"2021","unstructured":"Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of ascites in patients with cirrhosis: an update. J Clin Med. 2021, 10:5226. 10.3390\/jcm10225226","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-003-0050-5","article-title":"Treatment of ascites","volume":"6","author":"Choudhury J","year":"2003","unstructured":"Choudhury J, Sanyal AJ. Treatment of ascites. Curr Treat Options Gastroenterol. 2003, 6:481-91. 10.1007\/s11938-003-0050-5","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315580069","article-title":"Management of cirrhotic ascites","volume":"6","author":"Pedersen JS","year":"2015","unstructured":"Pedersen JS, Bendtsen F, M\u00f8ller S. Management of cirrhotic ascites. Ther Adv Chronic Dis. 2015, 6:124-37. 10.1177\/2040622315580069","journal-title":"Ther Adv Chronic Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: from pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne LS","year":"2020","unstructured":"Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: from pathophysiology to novel therapeutics. World J Gastroenterol. 2020, 26:6111-40. 10.3748\/wjg.v26.i40.6111","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04426.x","article-title":"The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites","volume":"32","author":"Misra VL","year":"2010","unstructured":"Misra VL, Vuppalanchi R, Jones D, Hamman M, Kwo PY, Kahi C, Chalasani N. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther. 2010, 32:1044-50. 10.1111\/j.1365-2036.2010.04426.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"56","author":"Singh V","year":"2012","unstructured":"Singh V, Dhungana SP, Singh B, et al.. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2012, 56:348-54. 10.1016\/j.jhep.2011.04.027","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X14564673","article-title":"Treatment and management of ascites and hepatorenal syndrome: an update","volume":"8","author":"Lenz K","year":"2015","unstructured":"Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol. 2015, 8:83-100. 10.1177\/1756283X14564673","journal-title":"Therap Adv Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.012","article-title":"Human serum albumin, systemic inflammation, and cirrhosis","volume":"61","author":"Arroyo V","year":"2014","unstructured":"Arroyo V, Garc\u00eda-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014, 61:396-407. 10.1016\/j.jhep.2014.04.012","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez J","year":"2019","unstructured":"Fern\u00e1ndez J, Cl\u00e0ria J, Amor\u00f3s A, et al.. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019, 157:149-62. 10.1053\/j.gastro.2019.03.021","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S377494","article-title":"Response guided slow infusion of albumin, vasoconstrictors and furosemide improves ascites mobilization and survival in acute on chronic liver failure: a proof-of-concept study","volume":"15","author":"Pande G","year":"2022","unstructured":"Pande G, Hatti M, Rai MK, et al.. Response guided slow infusion of albumin, vasoconstrictors and furosemide improves ascites mobilization and survival in acute on chronic liver failure: a proof-of-concept study. J Inflamm Res. 2022, 15:5027-39. 10.2147\/JIR.S377494","journal-title":"J Inflamm Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58121780","article-title":"Impact of albumin binding function on pharmacokinetics and pharmacodynamics of furosemide","volume":"58","author":"Klinkmann G","year":"2022","unstructured":"Klinkmann G, Klammt S, J\u00e4schke M, Henschel J, Gloger M, Reuter DA, Mitzner S. Impact of albumin binding function on pharmacokinetics and pharmacodynamics of furosemide. Medicina (Kaunas). 2022, 58:1780. 10.3390\/medicina58121780","journal-title":"Medicina (Kaunas)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper EB","year":"2023","unstructured":"Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA. 2023, 329:1589-602. 10.1001\/jama.2023.5997","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02272.x","article-title":"Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis","volume":"30","author":"Salerno F","year":"2010","unstructured":"Salerno F, Guevara M, Bernardi M, et al.. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010, 30:937-47. 10.1111\/j.1478-3231.2010.02272.x","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S136578","article-title":"Management of refractory cirrhotic ascites: challenges and solutions","volume":"10","author":"Fukui H","year":"2018","unstructured":"Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018, 10:55-71. 10.2147\/HMER.S136578","journal-title":"Hepat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0104","article-title":"Management of refractory ascites","volume":"29","author":"Wong F","year":"2023","unstructured":"Wong F. Management of refractory ascites. Clin Mol Hepatol. 2023, 29:16-32. 10.3350\/cmh.2022.0104","journal-title":"Clin Mol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10536-7","article-title":"Asia-Pacific association for study of liver guidelines on management of ascites in liver disease","volume":"17","author":"Singh V","year":"2023","unstructured":"Singh V, De A, Mehtani R, et al.. Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int. 2023, 17:792-826. 10.1007\/s12072-023-10536-7","journal-title":"Hepatol Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12166","article-title":"Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography","volume":"3","author":"Premkumar M","year":"2019","unstructured":"Premkumar M, Rangegowda D, Kajal K, Khumuckham JS. Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open. 2019, 3:322-8. 10.1002\/jgh3.12166","journal-title":"JGH Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90441-6","article-title":"Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites","volume":"94","author":"Llach J","year":"1988","unstructured":"Llach J, Gin\u00e8s P, Arroyo V, et al.. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988, 94:482-7. 10.1016\/0016-5085(88)90441-6","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.031","article-title":"Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting","volume":"81","author":"Nadim MK","year":"2024","unstructured":"Nadim MK, Kellum JA, Forni L, et al.. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024, 81:163-83. 10.1016\/j.jhep.2024.03.031","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.06.006","article-title":"Current pharmacologic therapies for hepatorenal syndrome-acute kidney injury","volume":"21","author":"Duong N","year":"2023","unstructured":"Duong N, Kakadiya P, Bajaj JS. Current pharmacologic therapies for hepatorenal syndrome-acute kidney injury. Clin Gastroenterol Hepatol. 2023, 21:S27-34. 10.1016\/j.cgh.2023.06.006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/01.elx.0000398638.27770.14","article-title":"Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites","volume":"1","author":"Oda AM","year":"20111","unstructured":"Oda AM, Basuni AA, Badran HM, Aziz WF, Rewisha EA, Waked IA. Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites. Egypt Liver J. 20111, 1:61-68. 10.1097\/01.elx.0000398638.27770.14","journal-title":"Egypt Liver J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01778.x","article-title":"The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study","volume":"29","author":"Tandon P","year":"2009","unstructured":"Tandon P, Tsuyuki RT, Mitchell L, et al.. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009, 29:169-74. 10.1111\/j.1478-3231.2008.01778.x","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites","volume":"46","author":"Kalambokis G","year":"2007","unstructured":"Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol. 2007, 46:213-21. 10.1016\/j.jhep.2006.09.012","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13250","article-title":"Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study","volume":"37","author":"Rai N","year":"2017","unstructured":"Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A, Singh V. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver Int. 2017, 37:406-14. 10.1111\/liv.13250","journal-title":"Liver Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5754\/hge14666","article-title":"Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial","volume":"61","author":"Ali A","year":"2014","unstructured":"Ali A, Farid S, Amin M, Kassem M, Al-Garem N. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. Hepatogastroenterology. 2014, 61:1915-24. 10.5754\/hge14666","journal-title":"Hepatogastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27483","article-title":"Midodrine in liver cirrhosis with ascites: a systematic review and meta-analysis","volume":"14","author":"Shrestha DB","year":"2022","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, et al.. Midodrine in liver cirrhosis with ascites: a systematic review and meta-analysis. Cureus. 2022, 14:e27483. 10.7759\/cureus.27483","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0 E","year":"2018","unstructured":"Sol\u00e0 E, Sol\u00e9 C, Sim\u00f3n-Talero M, et al.. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018, 69:1250-9. 10.1016\/j.jhep.2018.08.006","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni P","year":"2018","unstructured":"Caraceni P, Riggio O, Angeli P, et al.. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018, 391:2417-29. 10.1016\/S0140-6736(18)30840-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311887-midodrine-and-weekly-albumin-therapy-in-patients-with-cirrhosis-and-diuretic-intractable-or-recurrent-ascites-a-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:37:54Z","timestamp":1736156274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311887-midodrine-and-weekly-albumin-therapy-in-patients-with-cirrhosis-and-diuretic-intractable-or-recurrent-ascites-a-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.76988","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}